ENTO
Entero Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ENTO
Entero Therapeutics, Inc.
A biopharmaceutical company that develops targeted, non-systemic therapies for gastrointestinal diseases
777 Yamato Road, Suite 502, Boca Raton, Florida 33431
--
Entero Therapeutics, Inc., was established in Delaware on January 30, 2014. The company is a clinical-stage biopharmaceutical company engaged in the treatment, research and development of non-systemic biological agents for patients with gastrointestinal disorders.
Company Financials
EPS
ENTO has released its 2023 Q3 earnings. EPS was reported at -0.46, versus the expected -0.61, beating expectations. The chart below visualizes how ENTO has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
